Spin-offs

EPCure

| by: Rambam

Project Overview:Product: Endothelial progenitor cells, providing an optimal solution for bone regeneration.

EPCureEPCure

Need: The Bone regeneration market with is evaluated at $6B, however current solutions suffer from significant limitations.

Status: successful pre-clinical trials (orthopedic and Cranio-maxillofacial). Perusing cleft palate as 1st indication.

IP: Patent granted (2015).

Team:
Hadar Zigdon-Giladi, DMD, Ph.D. - Founder
Deputy Director, Department of periodontology, Rambam HCC. An author of multiple publications and winner of multiple honors, most recently (2016) the Zigler prize for excellent research in translational medicine, Bruce Rappaport Faculty of Medicine, Technion, Israel.

Danny Weiss
Life science entrepreneur and executive. Previous positions include CardioLogic Innovations (CEO), WellSense Technologies (CEO), FriCSo (VP BD) and Comverse (Ticker: CMVT; Senior Director of BD). Multiple board positions.

Shosh Merchav, PhD, MBA
Active in the field of Regenerative Medicine for more than 30 years. Ex-Teva executive, highly experienced in managing preclinical to late-stage clinical product development. Previous Scientific Advisory Board member at MGVS and Cell Cure, Senior Advisor for Adjuvant Partners, and Voisin Life Science Regulatory Consulting and Professional evaluator for Horizon 2020 and Israel Innovation Authority.